Hypoxia prevents myeloma cells from maturing and might reduce the expression of signaling lymphocytic activation molecule family member 7 (SLAMF7) and CD38, which are the target of elotuzumab (ELO) and DARA or isatuximab (ISA), depending on non-genetic diversity, which is described in detail in Section 5.6, “Nongenetic clonal diversity” [71,72,73]. The gene discussed is CD38; the disease is plasma cell myeloma.